Longevity Global reposted this
CEO & Co-founder, NeuroAge Therapeutics | Founder & Executive Director, Longevity Global
I personally had a conference cancelled last week because of Trump's comms freeze. It was pretty weird to have a meeting of scientists and entrepreneurs who are working on a grant for ARPA-H no longer be able to meet and talk to each other one day before we were supposed to get on a plane. These meetings help us build better therapeutics and diagnostics for people with age-related diseases. I can't imagine what the point of this freeze would be.
I Help People Access Affordable Therapy @ Resolvve | Science and Technology Journalist
What impact does the #NIH freeze have on #Alzheimers research, #ClinicalTrials and #DrugDevelopment? For Being Patient I spoke with Sheeva Azma of Fancy Comma, LLC and Suzanne Schindler of Washington University in St. Louis to understand whether this is out of the norm and what it might mean for patients down the line. “This week we learned that review panels for major Alzheimer’s clinical trials that were meeting in early February have been cancelled,” Schindler said. "These review panels will presumably be re-scheduled, but the uncertainties and delays will negatively affect our research efforts.” As part of the simultaneous DEI ban, the FDA removed the “Diversity Action Plan” document as well as other documents on its website, which housed a wealth of information about recruitment of non-white participants to clinical trials. This information was originally shared to help ensure drugs are safe and effective across all racial groups. Alzheimer’s and dementia occur at disproportionately high rates in women and in Black and Hispanic populations. Drug trials have historically struggle to recruit non-white participants, making it impossible for scientists to understand whether drugs and diagnostic tests work in these higher risk groups. https://lnkd.in/eDpUwsxM
